MedTrace Logo

IV Lacosamide: The Safety of Intravenous Lacosamide

NCT01981447 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-09-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of IV Lacosamide in children ages 4-35.

Conditions

Interventions

DRUG

IV Lacosamide

Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.

Sponsors & Collaborators

  • Le Bonheur Children's Hospital

    lead OTHER

Principal Investigators

  • James W Wheless, MD · Lebonheur Children's Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01981447 on ClinicalTrials.gov